Ionis Pharmaceuticals

Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases.

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, founded in 1989. Originally named Isis Pharmaceuticals, the company specializes in RNA-targeted therapeutics, particularly antisense oligonucleotides (ASOs), to address serious diseases in neurology, cardiology, and other critical areas. Ionis achieved its first FDA approval in 1998 with Vitravene, the first antisense drug, and has since developed a range of innovative therapies, including SPINRAZA, which transformed spinal muscular atrophy from a fatal condition into a manageable one. The company's core technology focuses on ASOs, which modulate RNA to control gene expression. Ionis has made significant advancements in ASO chemistry and has a robust pipeline of investigational RNA-targeted therapies. The company has shifted to a fully integrated model, allowing it to independently launch products while maintaining strategic partnerships with firms like Biogen and AstraZeneca for late-stage development and commercialization. This approach enables Ionis to leverage its expertise and accelerate market access for its innovative treatments.

Partnerships

 

  

  

 

  

  

 

  

  

Clients